Pre ‐emptive intraoperative administration of PCC4 in cardiac surgery patients at high risk of bleeding: A pilot study
ConclusionOverall patients received a low rate of blood transfusion, had minimal chest tube output, and there was a small incidence of right heart failure. Patients did not have an increased risk of adverse effects such as AKI or venous thromboembolism. A randomized controlled clinical trial comparing the observed dose and timing of PCC4 versus routine postoperative bleeding management with blood product transfusion is recommended.
Source: Journal of Cardiac Surgery - Category: Cardiovascular & Thoracic Surgery Authors: Joseph Elder,
Jennifer McComb,
Seth Lirette,
Bruce Herndon,
Gerald Yancey,
Asim Mohammed,
Hannah Copeland Tags: ORIGINAL ARTICLE Source Type: research
More News: Bleeding | Blood Transusion | Cardiology | Cardiovascular & Thoracic Surgery | Central Venous Catheterization | Clinical Trials | Coronary Artery Bypass Graft | Heart | Heart Failure | Heart Transplant | Kidney Transplant | Kidney Transplantation | Lung Transplant | Study | Thrombosis | Transplant Surgery | Transplants | Urology & Nephrology